company background image
RAP

ResApp HealthASX:RAP Stock Report

Market Cap

AU$60.1m

7D

2.9%

1Y

-30.0%

Updated

16 Oct, 2021

Data

Company Financials
RAP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RAP Overview

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.

Price History & Performance

Summary of all time highs, changes and price drops for ResApp Health
Historical stock prices
Current Share PriceAU$0.07
52 Week HighAU$0.04
52 Week LowAU$0.14
Beta0.43
1 Month Change-7.90%
3 Month Change66.67%
1 Year Change-30.00%
3 Year Change-68.18%
5 Year Change-85.86%
Change since IPO-98.72%

Recent News & Updates

Aug 26
Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

RAPAU Healthcare ServicesAU Market
7D2.9%0.2%0.9%
1Y-30.0%46.7%20.2%

Return vs Industry: RAP underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.

Return vs Market: RAP underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RAP's price volatile compared to industry and market?
RAP volatility
RAP Beta0.43
Industry Beta0.49
Market Beta1

Stable Share Price: RAP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: RAP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aTony Keatinghttps://www.resapphealth.com.au

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma.

ResApp Health Fundamentals Summary

How do ResApp Health's earnings and revenue compare to its market cap?
RAP fundamental statistics
Market CapAU$60.14m
Earnings (TTM)-AU$6.77m
Revenue (TTM)AU$69.73k

875.0x

P/S Ratio

-8.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RAP income statement (TTM)
RevenueAU$69.73k
Cost of RevenueAU$0
Gross ProfitAU$69.73k
ExpensesAU$6.84m
Earnings-AU$6.77m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0079
Gross Margin100.00%
Net Profit Margin-9,715.18%
Debt/Equity Ratio0%

How did RAP perform over the long term?

See historical performance and comparison

Valuation

Is ResApp Health undervalued compared to its fair value and its price relative to the market?

7.91x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RAP is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: RAP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RAP is overvalued based on its PB Ratio (7.9x) compared to the AU Healthcare Services industry average (3.8x).


Future Growth

How is ResApp Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ResApp Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has ResApp Health performed over the past 5 years?

-0.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RAP is currently unprofitable.

Growing Profit Margin: RAP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RAP is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare RAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: RAP has a negative Return on Equity (-89.09%), as it is currently unprofitable.


Financial Health

How is ResApp Health's financial position?


Financial Position Analysis

Short Term Liabilities: RAP's short term assets (A$7.5M) exceed its short term liabilities (A$1.7M).

Long Term Liabilities: RAP's short term assets (A$7.5M) exceed its long term liabilities (A$120.2K).


Debt to Equity History and Analysis

Debt Level: RAP is debt free.

Reducing Debt: RAP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RAP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RAP has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 16% each year.


Dividend

What is ResApp Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RAP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Tony Keating

6.25yrs

Tenure

AU$358,476

Compensation

Dr. Anthony James Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement...


CEO Compensation Analysis

Compensation vs Market: Tony's total compensation ($USD266.07K) is about average for companies of similar size in the Australian market ($USD302.45K).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RAP's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: RAP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.


Top Shareholders

Company Information

ResApp Health Limited's employee growth, exchange listings and data sources


Key Information

  • Name: ResApp Health Limited
  • Ticker: RAP
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$60.144m
  • Shares outstanding: 859.20m
  • Website: https://www.resapphealth.com.au

Location

  • ResApp Health Limited
  • 100 Creek Street
  • Level 12
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.